Price movement over the last 24 hours
Abbott Laboratories vs iShares MSCI Japan ETF — how do they compare? Abbott Laboratories trades at $95 (market cap $166.94B), while iShares MSCI Japan ETF trades at $91.98. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares MSCI Japan ETF pays none, and iShares MSCI Japan ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | EWJ | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $96.97 |
52-Week Low | $82.57 | $71.69 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
EWJ, the iShares MSCI Japan ETF, trades at $95.27, up 2.29% on the day, with a bullish technical signal driven by moving averages. The ETF provides exposure to Japanese equities, with recent news highlighting yen volatility and strong export data. Key support is at $94, with resistance at $96. A dividend of $0.50 is scheduled for June 2026.
Outlook remains tied to Japan's economic trends and currency dynamics. Opportunities include AI-driven export growth, but risks involve yen weakness and geopolitical tensions. Investors should weigh Japan's monetary policy shifts and global market sentiment for directional cues.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →